SummaryInterpreting magnetic resonance imaging (MRI) changes after hypofractionated stereotactic radiotherapy for benign central nervous system neoplasms can be challenging for the clinician. This retrospective study quantitates the subtle changes with volumetric MRI measurements and analyzes the changes over time. Temporal changes in tumor size, toxicity, and correlation with neuroradiologist interpretation are reported. Local control was excellent, and toxicity was low. We noted a mild discordance between the radiology report and MRI measurements, suggesting a clinical use for volumetric measurements.

Introduction {#sec1}
============

The management of benign meningiomas and vestibular schwannomas can be associated with unique challenges. Because these lesions are rarely life threatening, the decision to treat is often determined by current symptoms or the potential for worsening symptoms and the associated changes in quality of life. Potential treatments include surgical resection, radiation therapy, and close observation. The optimal treatment depends on tumor- and patient-related factors plus clinician and patient preferences.

Surgical management remains the first-line treatment for select patients when tumor resection would improve symptoms from mass effect[@bib1], [@bib2] or when surgery is potentially curative with gross total resection.[@bib3], [@bib4] However, surgery may pose challenges, depending on the intracranial location of the tumor, and includes risk of complications such as infection, bleeding, and neurologic loss. Radiation therapy is an alternative to surgery, especially for patients with benign tumors that are not amenable to surgical resection or recur after surgery.[@bib5], [@bib6], [@bib7], [@bib8]

Radiation therapy options include conventionally fractionated radiation therapy, stereotactic single-fraction radiosurgery, and hypofractionated stereotactic radiation therapy (HFSRT). Prior studies of conventional radiation therapy for benign central nervous system neoplasms have reported excellent local control (\>80%), but patients must undergo 5 to 6 weeks of radiation therapy.[@bib9], [@bib10], [@bib11] Single-fraction stereotactic radiosurgery also has excellent local control for smaller benign intracranial neoplasms, but depending on tumor-related factors (eg, location, size), they can be associated with increased risk of complications such as tumor-related swelling, hearing loss, and cranial neuropathies.[@bib10], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16] HFSRT has the ability to balance the therapeutic ratio through fractionation and a short treatment course.[@bib17], [@bib18], [@bib19], [@bib20] However, the posttreatment changes of these tumors have not been well characterized radiographically, particularly after HFSRT.

Magnetic resonance imaging (MRI) is the most common method of assessing response to radiation therapy. Nevertheless, differentiating between tumor progression and radiation therapy effects can be difficult.[@bib21] Often the clinician relies on the radiologist's interpretation of post--radiation therapy changes, but changes such as tumor-related swelling, transient volume expansion (TVE), and central necrosis can challenge the radiologist.[@bib22] These radiation therapy effects may be more pronounced in shorter, high-dose treatments.[@bib23], [@bib24], [@bib25] Historically, MRI-based measurements of tumor expansion or shrinkage have been interpolated by using the maximal tumor dimensions for height, width, and anteroposterior diameter. When assessing tumor growth or shrinkage, 1- or 2-dimensional analysis may be insufficient for tumors that are irregularly shaped or multilobulated and may be subject to interobserver differences. Therefore volumetric measurements potentially are advantageous for analyzing tumor response to radiation therapy over time. The aim of our study was to quantitatively assess volumetric changes, toxicities, and clinical outcomes after HFSRT in patients with vestibular schwannomas or meningiomas.

Methods and materials {#sec2}
=====================

Study design and patient population {#sec2.1}
-----------------------------------

This study was approved by the Mayo Clinic Institutional Review Board. The reporting of this study is in compliance with the Strengthening the Reporting of Observational Studies in Epidemiology statement.[@bib26] We retrospectively identified all patients with vestibular schwannomas or meningiomas who were treated at Mayo Clinic (Phoenix, Arizona) (an academic tertiary medical center) with linear accelerator−based HFSRT from January 1, 2002, through December 31, 2014. To meet the inclusion criteria, patients had to be at least 18 years old, had to have received a radiographic diagnosis of a vestibular schwannoma or meningioma, and could not have received prior radiation therapy to the tumor site. Patients were required to have received HFSRT (ie, 3-5 treatments). Patients were excluded from analysis if they did not receive follow-up clinical evaluation at our institution or if they had only computed tomography imaging.

HFSRT technique {#sec2.2}
---------------

All patients were treated with a linear accelerator (Varian Medical Systems). Patient immobilization was achieved with a commercial head mask fixation system. Patients underwent a planning computed tomography scan of the brain, and image fusion was performed with dedicated pretreatment MRI thin-cut sequences. The gross tumor volume (GTV) was delineated as a contrast-enhancing tumor demonstrated on T1 postgadolinium MRI imaging. The clinical target volume was equal to the GTV. The planning target volume was generated by the geometric expansion of GTV plus a margin (median, 2 mm; range, 0-3 mm). Patients were treated daily with image guidance. The median radiation dose was 25 Gy in 5 fractions (range, 18 Gy \[3 fractions\] to 35 Gy \[5 fractions\]). The prescribed dose was delivered to the 77% to 100% isodose line (mean, 89%) and normalized to the maximum dose to ensure coverage of at least 95% of the planning target volume with the prescription dose.

Clinical and radiologic follow-up {#sec2.3}
---------------------------------

After treatment, patients underwent clinical and radiologic MRI follow-up at 3- to 12-month intervals. All patients included in this study had pretreatment MRI imaging with at least 2 posttreatment MRI scans. A comprehensive clinical evaluation and neurologic examination were performed before treatment and at each clinical follow-up visit.

MRI volumetric assessment and response criteria {#sec2.4}
-----------------------------------------------

All posttreatment MRI scans was imported into the radiation planning system and contoured by 1 individual (K.R.F.). Volumetric measurements were generated retrospectively by outlining the GTV, including cystic changes, on each thin-cut slice of contrast-enhanced T1 series before and on each scan after HFSRT. The thinnest cuts available (slice thickness, 1-2.5 mm) were used for contouring. Volumetric changes were calculated for each available MRI scan and compared with the baseline tumor volume before radiation therapy. Percentage changes in size were reported as an increase, decrease, or no change compared with the original tumor volume.

Modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria[@bib27] were used to define disease progression and stability. Although RECIST criteria defined progression as an increase of 20% in the sum of the linear measurements, we used a volumetric approach in which ≥20% change in volume was considered progressive disease. Stable disease was defined as no change or a volume change \<30%. Partial response to treatment was defined as at least a 30% decrease in volume. Local control was defined as either stable disease or a partial response to treatment. TVE was defined as an increase of more than 20% from baseline with a subsequent decrease to within 20% of baseline. TVE patients were not defined as those with progression but were categorized based on their final volume size relative to baseline.

All diagnostic MRI scans were read and interpreted by a member of the neuroradiology department (G.P.F.). Tumor size was characterized as increased, decreased, or no change based on the diameter change of the tumor measured from the coronal, sagittal, and axial cross-sections. If the neuroradiologist's interpretation of a linear change agreed with our interpretation of a volumetric change (increase, decrease, or stable disease), this was considered concordant. If the report specified a change in size but the volumetric change was stable (within 20% of baseline), this was considered discordant. If a report specified no change when a volumetric change exceeding 20% was measured, this was also considered discordant.

Results {#sec3}
=======

We identified 43 patients with 182 MRI scans who were treated with HFSRT during the study period. Baseline characteristics are shown in [Table 1](#tbl1){ref-type="table"}. The median (range) duration of follow-up was 29 (6-142) months.Table 1Baseline characteristics (N = 43)CharacteristicValueMale sex, n (%)20 (47)Age, median (range), y68 (33-87)Primary intracranial tumor, n (%) Vestibular schwannoma34 (79) Meningioma9 (21)Gross tumor volume, median, cm^3^3.1Radiation dose and fractionation, n (%) 35 Gy, 5 treatments2 (5) 27.5 Gy, 5 treatments1 (2) 25 Gy, 5 treatments23 (53) 21 Gy, 3 treatments2 (5) 20 Gy, 5 treatments12 (28) 20 Gy, 4 treatments1 (2) 18 Gy, 3 treatments2 (5)MRI scans per patient after radiation therapy, median (range) Vestibular schwannoma3 (2-11) Meningioma4 (2-7)[^1]

[Figure 1](#fig1){ref-type="fig"} shows the final change in volume for patients with vestibular schwannoma; compared with baseline, 12 patients (35%) had a partial response to treatment, 14 (41%) remained stable, and 8 (24%) had more than 20% volumetric growth. The largest expansion was observed in patient 34, who had a very small acoustic neuroma at presentation. This lesion progressed to a volumetric change of 800%. The lesion ultimately was resected. Post-HFSRT changes in vestibular schwannoma volume over time are shown in [Figure 2](#fig2){ref-type="fig"}.Figure 1Final change in volume for patients with vestibular schwannoma. Numbers represent individual patients.Figure 2Changes in vestibular schwannoma volume after hypofractionated stereotactic radiation therapy (n = 34). One patient had a maximum volume change of 800% (change at last follow-up).

[Figure 3](#fig3){ref-type="fig"} shows the final change in volume for patients with meningioma; compared with baseline, 6 patients (67%) had a partial response to treatment, 3 (33%) remained stable, and no patients had a progressive expansion. Post-HFSRT changes in volume over time are shown in [Figure 4](#fig4){ref-type="fig"}.Figure 3Final change in volume for patients with meningioma. Numbers represent individual patients.Figure 4Changes in meningioma volume after hypofractionated stereotactic radiation therapy (n = 9).

TVE was identified in 17 patients with vestibular schwannoma (50%). Median time of TVE was 6 months (range, 3-13 months), with a return to pretreatment size or decrease in size identified within a median time of 13 months (range, 6-59 months). Two patients with meningioma (22%) had TVE at a median time of 2.5 months (range, 2-3 months), with a return to pretreatment size or a decrease in size within a median time of 9.5 months (range, 7-12 months).

TVE was associated with increased toxicity in 11 patients (65%) with vestibular schwannoma. Symptoms included hearing loss (n = 5), imbalance (n = 3), dizziness (n = 3), facial paresthesias (n = 2), tinnitus (n = 2), headache (n = 2), and vertigo (n = 2), with some patients experiencing multiple symptoms. Hearing loss persisted in all patients, and the other symptoms resolved for 6 patients (55%) within a median time of 6.5 months (range, 1-15 months). A total of 6 patients (30%), 5 with vestibular schwannoma and 1 with meningioma, had grade 2 toxicity requiring corticosteroids. Toxicity that included speech difficulty and weakness was seen in 1 of the 2 patients with meningioma, with symptoms resolving within 12 months after radiation.

Tumor volumetric assessment for each follow-up MRI scan was compared with the neuroradiologist's interpretation of size change for each report. The assessment was concordant with the volumetric change (in terms of tumor regression, stability, or progression) for 155 reports (85%). For 24 reports (13%), the report specified no change in size, but the volumetric change (increase or decrease) exceeded 20%. Furthermore, for 3 reports (2%), a report specified a change in size, but no volumetric change was noted.

Local control was observed in 35 patients (81.4%) at the time of last follow-up. Progression or TVE was found in 8 patients (18.6%). Progression did not occur in any patients with meningioma. A weak correlation was identified between the changes in volume as a function of time after completion of radiation therapy ([Fig 5](#fig5){ref-type="fig"}).Figure 5Volume change in tumor size from baseline over time, stratified by tumor type.

Discussion {#sec4}
==========

Our findings indicate that subtle posttreatment MRI changes after HFSRT are common and difficult to interpret. This study provides more accurate 3-dimensional MRI volumetric data, with changes observed over time. We believe that this information supplements the neuroradiologist's report and helps the clinician appropriately counsel patients. Although we generally found good correlation between volumetric measurements and the neuroradiologist's interpretation using RECIST criteria, we noted a 15% discordance rate.

Overall, HFSRT delivered high local control rates with low reported toxicity. TVE was fairly common, although generally self-limited. Several cases were associated with short-term toxicity. Our study adds evidence to the literature reporting that this fractionation regimen is a reasonable option.

The natural disease course of vestibular schwannomas and grade 1 meningiomas is a relatively slow potential doubling time, growth rate, and mitotic rate. Because treatment response rates differ based on the activity of the cells in question, slow-growing cells will likely also respond more slowly to radiation therapy. Furthermore, reabsorption of killed tumor cell populations may not necessarily occur, leaving the lesion size unchanged. The opposite effect can occur as well, with lesions first increasing in size as a secondary effect of radiation and then regressing; TVE potentially causes symptoms and can be a therapeutic complication.[@bib22], [@bib28], [@bib29] Thus, one of the main challenges for the clinician is interpreting post--radiation therapy MRI scans and reports. Differentiating among partial response, stable change, TVE, and clear tumor progression from a single scan is difficult. In general, multiple scans over months to years are needed to draw a more accurate conclusion.

The purpose of this study was to provide more objective data on how these tumors behave after treatment by using more accurate MRI volumetric measurements. Although RECIST criteria are useful for the interpretation of these radiologic changes after radiation therapy for malignant disease,[@bib27] they are not ideal for benign intracranial neoplasms because of the small changes typically found after treatment. The RECIST criteria require a relative change of more than 20% and an absolute change of more than 5 mm from baseline. They also considered lesions smaller than 10 mm to be nonmeasurable.

In our series, the volumetric measurement was concordant with the neuroradiologist's interpretation for 155 reports (85%). For 24 reports (13%), discordance was attributed to a volumetric change exceeding 20% and the neuroradiologist reporting no change. Interestingly, many of these patients had reported toxicities, which added to the clinical dilemma when the MRI scan was interpreted as showing no change. By using MRI volumes to define progression, small differences in linear measurements would be mitigated because each change on a thin-slice MRI scan would have a smaller effect on the overall volume.

In our study, we were able to achieve a high local control rate of 83% with the use of HFSRT; this rate is likely an underestimation as a result of TVE changes and date of last follow-up. TVE occurred in 19 of 43 lesions (44%). This high rate was mostly attributed to treatment-related central necrosis, which caused a temporary increase in overall volume. For patients with vestibular schwannoma, the temporary size increase caused symptoms in 61%; at last follow-up, symptoms had resolved in 55% of patients. However, hearing loss persisted in all affected patients with vestibular schwannoma.

Few studies have investigated the role of volumetric MRI measurements in patients with benign central nervous system neoplasms who have been treated with single-fraction radiosurgery, conventional fractionated stereotactic radiation therapy, or HFSRT.[@bib17], [@bib19], [@bib20] All report good local control rates with low toxicity. However, the differences in definitions for local control and progression makes direct comparisons difficult. Matsuo et al[@bib30] evaluated patients with vestibular schwannoma treated with single-fraction radiosurgery and used a volume change of 20% to define shrinkage or growth. They noted a transient enlargement pattern in 54.5%, with a 27% shrinkage rate and an 11% progression rate. van de Langenberg et al[@bib31] examined patients with vestibular schwannoma treated with single-fraction radiosurgery or conventional fractionated stereotactic radiation therapy and used a volume change of 19.7% to define shrinkage or growth. They noted that 65% of patients had shrinkage, 13% had progression, and 54% had transient enlargement. Harrison et al[@bib32] examined patients receiving single-fraction radiosurgery for meningiomas, defining progression as \>15% volume change and regression as ≤15% volume change. They found regression in 67% and progression in 7%. Allowing for differences in definition, these results are similar to our findings.

In terms of HFSRT, Gorman et al[@bib20] evaluated the role of HFSRT in skull-based meningiomas and defined a partial response as a ≥50% decrease in maximum tumor diameter and stable disease as being between a \<25% increase and \<50% decrease in maximum tumor diameter. Mahadevan et al[@bib17] evaluated clinical outcomes after HFSRT for benign skull-based tumors and reported local control as size stability and nonprogression in the MRI scan. Kapoor et al[@bib33] defined radiographic progression for any tumor greater than the baseline volume and significant radiographic progression when the tumor volume was more than double the treatment volume. They found that patients with tumor volumes \<1 cm^3^ were more likely to have significant radiologic progression compared with patients with larger-volume tumors. Our study is the first to compare volumetric measurements and a neuroradiologist's interpretation.

Limitations of this study include the differences in slice thickness obtained during the MRI scan, which can markedly affect volumetric measurements (particularly for very small lesions), intraobserver differences in volumetric measurements and radiologist interpretation, and the impact of TVE on final volume calculations.

Conclusions {#sec5}
===========

Volumetric MRI measurements provide additional information that may be used to correlate changes in tumor volume with symptoms or toxicities, if they arise. Clinicians should be aware of the possible discordance between radiologic reports and volume measurements, particularly in managing patients with symptoms. Continued follow-up and medical management of symptoms is important before determining true disease progression. HFSRT remains a good option for excellent local control and minimal toxicity in patients with vestibular schwannomas and meningiomas.
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[^1]: *Abbreviation:* MRI = magnetic resonance imaging.
